Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INSM Stock Forecast 2026-2027
$139.52
Current Price
$30.07B
Market Cap
Buy 19
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to INSM Price Targets
+72.7%
To High Target of $241.00
+51.2%
To Median Target of $211.00
+19.0%
To Low Target of $166.00
INSM Price Momentum
-0.4%
1 Week Change
-6.2%
1 Month Change
+85.9%
1 Year Change
-19.8%
Year-to-Date Change
-34.4%
From 52W High of $212.75
+131.0%
From 52W Low of $60.40
📊 TOP ANALYST CALLS
Did INSM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Insmed is one of their latest high-conviction picks.
Latest INSM Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, INSM has a bullish consensus with a median price target of $211.00 (ranging from $166.00 to $241.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $139.52, the median forecast implies a 51.2% upside. This outlook is supported by 19 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ritu Baral at TD Cowen, projecting a 72.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INSM Analyst Ratings
19
Buy
1
Hold
0
Sell
INSM Price Target Range
Low
$166.00
Average
$211.00
High
$241.00
Current: $139.52
Latest INSM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INSM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2026 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $204.00 |
| Feb 23, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Reiterates | $230.00 |
| Feb 20, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $208.00 |
| Jan 30, 2026 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $162.00 |
| Jan 28, 2026 | Barclays | Eliana Merle | Overweight | Initiates | $231.00 |
| Jan 23, 2026 | Roth Capital | Adam Walsh | Buy | Initiates | $212.00 |
| Jan 21, 2026 | RBC Capital | Leonid Timashev | Outperform | Maintains | $200.00 |
| Jan 6, 2026 | UBS | Ashwani Verma | Buy | Maintains | $215.00 |
| Dec 18, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $230.00 |
| Dec 18, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $195.00 |
| Dec 18, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $221.00 |
| Dec 18, 2025 | Goldman Sachs | Andrea Tan | Buy | Maintains | $225.00 |
| Dec 18, 2025 | TD Cowen | Ritu Baral | Buy | Maintains | $241.00 |
| Dec 16, 2025 | Cantor Fitzgerald | Olivia Brayer | Overweight | Maintains | $230.00 |
| Dec 16, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $234.00 |
| Dec 15, 2025 | Goldman Sachs | Andrea Tan | Buy | Maintains | $258.00 |
| Dec 11, 2025 | TD Cowen | Ritu Baral | Buy | Maintains | $269.00 |
| Dec 1, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $256.00 |
| Nov 20, 2025 | TD Cowen | Ritu Baral | Buy | Maintains | $231.00 |
| Oct 31, 2025 | UBS | Trung Huynh | Buy | Maintains | $223.00 |
Insmed Inc. (INSM) Competitors
The following stocks are similar to Insmed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Insmed Inc. (INSM) Financial Data
Insmed Inc. has a market capitalization of $30.07B with a P/E ratio of -21.7x. The company generates $606.42M in trailing twelve-month revenue with a -210.5% profit margin.
Revenue growth is +152.6% quarter-over-quarter, while maintaining an operating margin of -94.6% and return on equity of -249.3%.
Valuation Metrics
Market Cap
$30.07B
Enterprise Value
$30.33B
P/E Ratio
-21.7x
PEG Ratio
-1.3x
Price/Sales
51.1x
Growth & Margins
Revenue Growth (YoY)
+152.6%
Gross Margin
+83.2%
Operating Margin
-94.6%
Net Margin
-210.5%
EPS Growth
+152.6%
Financial Health
Cash/Price Ratio
+4.8%
Current Ratio
3.8x
Debt/Equity
101.4x
ROE
-249.3%
ROA
-29.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Insmed Inc. (INSM) Business Model
About Insmed Inc.
What They Do
Develops therapies for serious lung diseases.
Business Model
Insmed Inc. generates revenue primarily through the commercialization of its innovative therapies, with its flagship product ARIKAYCE approved for treating a rare lung disease. The company also advances a pipeline of promising therapies aimed at addressing unmet medical needs in rare and serious respiratory conditions.
Additional Information
Founded in 1988 and headquartered in Bridgewater, New Jersey, Insmed Inc. operates globally with a focus on rigorous clinical research and patient-centric approaches. The company's commitment to addressing rare pulmonary disorders positions it well within the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,664
CEO
Mr. William H. Lewis J.D., M.B.A.
Country
United States
IPO Year
2000
Website
www.insmed.comInsmed Inc. (INSM) Latest News & Analysis
Latest News
Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
3 days ago
Quick Summary
Insmed Incorporated (INSM) presented at the Leerink Global Healthcare Conference 2026, providing updates on its business and strategic initiatives.
Why It Matters
Insmed's presentation at a major healthcare conference highlights its strategic direction and potential growth, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Insmed Incorporated granted inducement awards to 85 new employees, indicating expansion and investment in talent as part of its focus on developing therapies for serious diseases.
Why It Matters
Insmed's inducement awards for new employees signal growth and confidence in its pipeline, potentially leading to innovation and increased shareholder value.
Source: PRNewsWire
Market Sentiment:
Neutral
Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript
11 days ago
Quick Summary
Insmed Incorporated (INSM) presented at the TD Cowen 46th Annual Health Care Conference, sharing insights on their developments and strategies in the healthcare sector.
Why It Matters
Insmed's presentation at a major healthcare conference can signal strategic developments, potential partnerships, or product updates, impacting its stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Eli Lilly shares rose due to Zepbound's strong launch. Cidara Therapeutics saw a significant increase after Merck's $9.2 billion acquisition. Doximity's stock fell on weak guidance.
Why It Matters
Eli Lilly's share rise reflects successful product launches, enhancing growth prospects. Cidara's acquisition boosts value, while Doximity's poor guidance signals potential challenges, affecting investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
The portfolio had strong absolute returns in Q4 and 2025 but underperformed the MSCI All Country World Small Mid Index. Health care stock selection was the top performer, with strong demand for optical components noted.
Why It Matters
Strong returns signal portfolio strength, but underperformance vs. the index raises concerns. Growth in AI-driven data centers and health care stock selection can influence future performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Insmed Incorporated (INSM) held its Q4 2025 earnings call, discussing financial results and company developments. Further details can be found in the transcript.
Why It Matters
Insmed's Q4 2025 earnings call provides insights into financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About INSM Stock
What is Insmed Inc.'s (INSM) stock forecast for 2026?
Based on our analysis of 31 Wall Street analysts, Insmed Inc. (INSM) has a median price target of $211.00. The highest price target is $241.00 and the lowest is $166.00.
Is INSM stock a good investment in 2026?
According to current analyst ratings, INSM has 19 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $139.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INSM stock?
Wall Street analysts predict INSM stock could reach $211.00 in the next 12 months. This represents a 51.2% increase from the current price of $139.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Insmed Inc.'s business model?
Insmed Inc. generates revenue primarily through the commercialization of its innovative therapies, with its flagship product ARIKAYCE approved for treating a rare lung disease. The company also advances a pipeline of promising therapies aimed at addressing unmet medical needs in rare and serious respiratory conditions.
What is the highest forecasted price for INSM Insmed Inc.?
The highest price target for INSM is $241.00 from Ritu Baral at TD Cowen, which represents a 72.7% increase from the current price of $139.52.
What is the lowest forecasted price for INSM Insmed Inc.?
The lowest price target for INSM is $166.00 from at , which represents a 19.0% increase from the current price of $139.52.
What is the overall INSM consensus from analysts for Insmed Inc.?
The overall analyst consensus for INSM is bullish. Out of 31 Wall Street analysts, 19 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $211.00.
How accurate are INSM stock price projections?
Stock price projections, including those for Insmed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 12:04 PM UTC